Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort

Description

The purpose of this research use only (RUO) study is to detect genomic structural variants (SVs) in human DNA by Optical Genome Mapping (OGM) using the Bionano Genomics Saphyr system. SVs are a type of genetic alternation that includes deletions, duplications, and both balanced and unbalanced rearrangements (ex: inversions or translocations), as well as specific repeat expansions and contractions. The results of OGM analysis will be compared to prior clinical genetic test results to determine how OGM compares to current standard of care (SOC) clinical test methods such as chromosomal microarray analysis (CMA), karyotyping, Southern blot analysis, polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), and/or next generation sequencing (NGS), etc.

Conditions

Developmental Disability, Intellectual Disability, Autism Spectrum Disorder, Congenital Anomaly, Fragile X Syndrome, Facioscapulohumeral Muscular Dystrophy 1

Study Overview

Study Details

Study overview

The purpose of this research use only (RUO) study is to detect genomic structural variants (SVs) in human DNA by Optical Genome Mapping (OGM) using the Bionano Genomics Saphyr system. SVs are a type of genetic alternation that includes deletions, duplications, and both balanced and unbalanced rearrangements (ex: inversions or translocations), as well as specific repeat expansions and contractions. The results of OGM analysis will be compared to prior clinical genetic test results to determine how OGM compares to current standard of care (SOC) clinical test methods such as chromosomal microarray analysis (CMA), karyotyping, Southern blot analysis, polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), and/or next generation sequencing (NGS), etc.

Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort

Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort

Condition
Developmental Disability
Intervention / Treatment

-

Contacts and Locations

Atlanta

Praxis Genomics, Atlanta, Georgia, United States, 30328

Augusta

Augusta University Research Institute, Augusta, Georgia, United States, 30912

Iowa City

University of Iowa Hospitals & Clinics, Molecular Pathology, Iowa City, Iowa, United States, 52242

New York

Columbia University Irving Medical Center, New York, New York, United States, 10032

W. Henrietta

DNA Microarray CGH Laboratory, Department of Pathology, University of Rochester Medical Center, W. Henrietta, New York, United States, 14586

Greenwood

Greenwood Genetic Center, Greenwood, South Carolina, United States, 29646

Salt Lake City

Lineagen (A Bionano Genomics Company), Salt Lake City, Utah, United States, 84109

Milwaukee

Medical College of Wisconsin, Milwaukee, Wisconsin, United States, 53226

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Individual with a genomic aberration identified by CMA, karyotyping, Southern blot analysis, PCR, FISH, and/or NGS or other standard of care (SOC) genetic testing technology whose clinical test results are available to compare with results from OGM.
  • 2. Patients with prior negative SOC genetic testing results whose results are available to compare with results from OGM.
  • 1. Any individual who opted-out of research at the testing laboratory.
  • 2. An individual whose genetic test contains the following variants: pathogenic sequence variants, abnormalities involving acrocentric p-arms and centromeres, below 20% for mosaicism, and tetraploidy.

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Bionano Genomics,

Alka Chaubey, PhD, FACMG, PRINCIPAL_INVESTIGATOR, Bionano Genomics

Study Record Dates

2024-06-30